Articles related to ESOPHAGEAL CANCER

This comprehensive review underscores the increasing incidence of esophageal adenocarcinoma and highlights the integration of advanced endoscopic techniques and novel screening tools, which are critical in the early detection and management of this challenging disease.

This recent cohort study shows that the incidence rate of oesophageal adenocarcinoma in non-erosive GERD patients aligns closely with the general population. Consider revisiting your endoscopic monitoring protocols based on these findings.

Discover how Roswell Park’s phase 2 clinical trials are exploring the potential of propranolol to enhance the efficacy of immunotherapies in treating esophageal cancer. This could represent a significant shift in treatment protocols.

The field of gastric and esophageal cancer treatment is witnessing remarkable advancements through targeted therapies and immunotherapies. Explore the latest clinical trials and discoveries that are redefining the standard of care for these traditionally difficult-to-treat cancers.

In a recent study presented at the American Association for Thoracic Surgery (AATS) Annual Meeting, researchers reported that more than 75% of patients who received neoadjuvant chemotherapy combined with an immune checkpoint inhibitor (ICI) were still alive and event-free at 1 year. The treatment was also well-tolerated, with a manageable rate of side effects. The 1-year event-free survival rate was 78.3%, and the 1-year overall survival rate was 88.0%. The postoperative complication rate was 35.6%, and the rate of grade 3 or higher treatment-related adverse events was 18.1%. The most common side effects were leukopenia, neutropenia, thrombocytopenia, anemia, and hyperglycemia. Overall, the results of this study suggest that neoadjuvant chemotherapy combined with an ICI is a safe and effective treatment option for patients with resectable esophageal cancer. The treatment was associated with a high rate of pCR and R0 resection, and the side effects were generally manageable.

Cancer Therapy Advisor provides a variety of resources, including regimens used to supplement the most recent treatment strategies. Examine all regimens here.